Research map: Topical gene therapy for severe recessive dystrophic epidermolysis bullosa: clinical outcomes and multidisciplinary management in three patients treated with beremagene geperpavec (B-VEC) in Italy – a case series

Back to the article

Papers in this map

  1. Epidemiology of Inherited Epidermolysis Bullosa Based on Incidence and Prevalence Estimates From the National Epidermolysis Bullosa Registry · Jo‐David Fine · 2016 · 315 citations · Cited by this paper
  2. Apremilast in osteoarthritis: exploring its therapeutic mechanisms · 2025 · Related
  3. Extracutaneous manifestations and complications of inherited epidermolysis bullosa · Jo‐David Fine · 2009 · 299 citations · Cited by this paper
  4. Deucravacitinib in dermatology: current indication and existing off-label data · 2026 · Related
  5. Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa · Shireen V. Guide · 2022 · 202 citations · Cited by this paper
  6. Tezepelumab for early-onset severe allergic asthma with persistent airflow limitation and small airway dysfunction: a treatable traits approach · 2025 · Related
  7. The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers · Anna L. Bruckner · 2020 · 192 citations · Cited by this paper
  8. Complete response to pembrolizumab in a paediatric patient with Lynch syndrome-associated colorectal cancer: a case report and review of immunotherapy-related bowel obstruction · 2026 · Related
  9. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial · Irina Gurevich · 2022 · 170 citations · Cited by this paper
  10. Overcoming disease progression in advanced endometrial cancer: a clinical case of sequential therapies · 2025 · Related
  11. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study · Johannes Steffen Kern · 2022 · 78 citations · Cited by this paper
  12. Body composition and cardiometabolic risk reduction following therapy with a multi-ingredient nutraceutical formulation: a real-life clinical study · 2026 · Related
  13. Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America · James Aaron Feinstein · 2018 · 49 citations · Cited by this paper
  14. Effectiveness of the antihistamine and anti-PAF effects of rupatadine in allergic diseases: off-label use in a case series study · 2025 · Related
  15. Epidemiology of inherited epidermolysis bullosa in Germany · Cristina Has · 2022 · 49 citations · Cited by this paper
  16. Primary hyperhidrosis: an updated review · 2025 · Related
  17. Practical management of epidermolysis bullosa: consensus clinical position statement from the European Reference Network for Rare Skin Diseases · Cristina Has · 2021 · 48 citations · Cited by this paper
  18. Real-world effectiveness of a phlebotonic formulation combining diosmin, Ruscus, Melilotus and Vitis vinifera on symptoms and quality of life in patients with chronic venous and lymphatic disease: results from the VIVEMA Stasis observational study · 2026 · Related
  19. Squamous Cell Carcinoma in Patients with Inherited Epidermolysis Bullosa: Review of Current Literature · Domenico Bonamonte · 2022 · 39 citations · Cited by this paper
  20. Emerging concepts in HIV pre-exposure prophylaxis: focus on twice-yearly lenacapavir · 2026 · Related
  21. Multidisciplinary care for patients with epidermolysis bullosa from birth to adolescence: experience of one Italian reference center · Chiara Retrosi · 2022 · 36 citations · Cited by this paper
  22. From Clinical Phenotype to Genotypic Modelling: Incidence and Prevalence of Recessive Dystrophic Epidermolysis Bullosa (RDEB) · Shaundra L. Eichstadt · 2019 · 34 citations · Cited by this paper
  23. Oleogel-S10 in Dystrophic Epidermolysis Bullosa: A Case Series Evaluating the Impact on Wound Burden Over Two Years · Mauricio Torres-Pradilla · 2024 · 15 citations · Cited by this paper
  24. Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa · M. Peter Marinkovich · 2025 · 12 citations · Cited by this paper
  25. Practical considerations relevant to treatment with the gene therapy beremagene geperpavec-svdt for dystrophic epidermolysis bullosa · Amy S. Paller · 2024 · 11 citations · Cited by this paper
  26. Topical Gene Therapy for Epidermolysis Bullosa · Aimee S. Payne · 2022 · 10 citations · Cited by this paper
  27. The Coming of Age of Topical Gene Therapy for Dystrophic Epidermolysis Bullosa · David V. Schaffer · 2022 · 5 citations · Cited by this paper
  28. Real-world case series: Birch triterpenes gel efficacy in 2 patients with junctional epidermolysis bullosa · Alexia Collins · 2025 · 3 citations · Cited by this paper
  29. Beremagene geperpavec (B‐ VEC ) for infantile dystrophic epidermolysis bullosa: Benefit of early intervention · Meropi Karakioulaki · 2025 · 3 citations · Cited by this paper
  30. Real‐World Experience With Oleogel‐S10 for Wounds in Epidermolysis Bullosa · Miodrag Davidovic · 2025 · 3 citations · Cited by this paper
  31. Quality of life in children and adults with epidermolysis bullosa: the QoL-REB explorative study · Cinzia Pilo · 2026 · 3 citations · Cited by this paper
  32. Efficacy and Safety of the Topical Gene Therapy Beremagene Geperpavec‐ svdt (B‐VEC) in an Open‐Label Study of Japanese Subjects With Dystrophic Epidermolysis Bullosa · Ken Natsuga · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)